Intersect ENT (XENT) Tops Q2 EPS by 5c; Guides FY16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Intersect ENT Reports Second Quarter 2016 Results
August 2, 2016 4:07 PM EDTRevenue Increased 27% Year Over Year; Gross Margin at 84%
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the second quarter ended June 30, 2016.
Second quarter 2016 revenue was $19.3 million, representing a 27% increase over the second quarter 2015. Second quarter 2016 gross margin was 84% compared to 81% in the second quarter 2015.Key recent product development milestones include:
... More